A Randomized Trial of Uninterrupted Warfarin versus Heparin Bridging in Transfemoral Coronary Angiography

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20160715001

Enrollment

Unknown

Registered

2016-07-15

Start date

2014-01-31

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

&#45

Interventions

molecular&#45

weight heparin (LMWH) is often administered as bridging therapy around the time of procedure (CAG).

Active Comparator Drug,Active Comparator Drug

Warfarin,Heparin

Warfarin is the main anticoagulant therapy in the prevention of thromboembolism in patients with atrial fibrillation or mechanical valve. The significant number of patients referred for coronary angio

i.e. less than 1.8,Either unfractionated heparin (UFH) or low&#45

Eligibility

Sex/Gender

All

Age

18 Years to 0 Years

Inclusion criteria

Inclusion criteria: 1. Age > 18 years 2. TO underwent elective transfemoral CAG and had received long-term warfarin therapy 3. To give inform consent

Exclusion criteria

Exclusion criteria: 1. The patients who are not willing to participate in the study 2. The patients who require adhoc percutaneous coronary intervention

Design outcomes

Primary

Measure	Time frame
Incidence of major vascular access site complications post CAG 24 hours after CAG Groin hematoma > 5 cm in diameter, pseudoaneurysm or arteriovenous fistula	—

Secondary

Measure	Time frame
The incidence of total vascular access site complications. 24 hours Number of site complication	—

Countries

Thailand

Contacts

Public ContactWanwarang WongCharoen

Faculty of Medicine, Chiang Mai University

bwanwarang@yahoo.com+66 5393 6716

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026